A Phase 1 trial of EB003 for the treatment of severe diarrhea induced by shiga-toxin (Stx) producing E. coli (STEC, leading to Hemolytic Uremic Syndrome)
Latest Information Update: 20 Jun 2021
At a glance
- Drugs EB 003 (Primary)
- Indications Diarrhoea
- Focus Adverse reactions
- Sponsors Eligo Bioscience
- 20 Jun 2021 New trial record
- 15 Jun 2021 According to an Eligo media release it is planning to initiate its first clinical trial for EB003 for the treatment of STEC in the second quarter of 2022.